Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)

This investigation is for anyone who acquired securities in Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) prior to April 8, 2024.

The Law Offices of Howard G. Smith believes that the Company and certain of its executives violated federal law. Specifically, the Law Offices of Howard G. Smith believes that the Company misled investors regarding its financial condition. More specifically, the Law Offices of Howard G. Smith believes that the Company misled investors by leading investors to believe that the Company would likely receive FDA approval for the Company’s Parkinson’s disease treatment, SPN-830, when the Company knew FDA approval was unlikely considering that the Company knew that it did not meet FDA standards for safe manufacture of the drug.

On April 8, 2024, Supernus announced that the FDA had issued a Complete Response Letter (“CRL”) in response to the Company’s New Drug Application for its Parkinson’s disease treatment, SPN-830. The CRL stated that “the review cycle for the application is complete, but that the application is not ready for approval in its present form.” Specifically, “two areas that require additional review by the FDA or additional information to be provided to the FDA,” respectively relating to product quality and the master file for the infusion device. On this news, the price of the Company’s stock dropped precipitously on unusually heavy trading volume.

The Law Offices of Howard G. Smith seeks to recover damages on behalf of class members. If you acquired securities in Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) prior to April 8, 2024 you may join the lawsuit by submitting your information online, or you may call the Law Offices of Howard G. Smith and speak to Mr. Smith directly to learn how he can protect your rights.